MCID: AST007
MIFTS: 65

Astrocytoma malady

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

Aliases & Descriptions for Astrocytoma:

Name: Astrocytoma 12 29 52 42 14 69
Cerebral Astrocytoma 12 69
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 42 D001254

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astocyte cells, a type of star-shaped glial cell, located in the cerebrum.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to pineal gland astrocytoma and juvenile astrocytoma. An important gene associated with Astrocytoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are ERK Signaling and Glioma. The drugs Afinitor and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial, and related phenotypes are Decreased sensitivity to paclitaxel and behavior/neurological

Wikipedia : 71 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 431)
id Related Disease Score Top Affiliating Genes
1 pineal gland astrocytoma 33.2 IDH1 NF1 TP53
2 juvenile astrocytoma 33.0 CDK4 EGFR GFAP IDH1 MGMT NES
3 grade iii astrocytoma 32.4 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
4 brain stem astrocytic neoplasm 31.8 GFAP MGMT SYP TP53
5 adult astrocytic tumour 30.9 CDK4 CDKN2A DMBT1 EGFR GFAP IDH1
6 central neurocytoma 29.9 GFAP NF1 SYP
7 pineoblastoma 29.7 GFAP SYP TP53
8 neurilemmoma 29.5 IDH1 NF1
9 colorectal cancer 29.0 CCND1 CDK4 CDKN2A EGFR IL1B MDM2
10 pilocytic astrocytoma 12.3
11 fibrillary astrocytoma 12.3
12 subependymal giant cell astrocytoma 12.2
13 spinal cord astrocytoma 11.9
14 cerebellar astrocytoma 11.9
15 pilomyxoid astrocytoma 11.9
16 gemistocytic astrocytoma 11.9
17 juvenile pilocytic astrocytoma 11.9
18 protoplasmic astrocytoma 11.9
19 optic nerve astrocytoma 11.9
20 childhood pilocytic astrocytoma 11.9
21 pilocytic astrocytoma of cerebellum 11.9
22 diencephalic astrocytomas 11.8
23 mixed oligodendroglioma-astrocytoma 11.8
24 desmoplastic infantile astrocytoma 11.8
25 childhood cerebral astrocytoma 11.8
26 desmoplastic infantile astrocytoma/ganglioglioma 11.8
27 mixed astrocytoma-ependymoma 11.7
28 childhood optic tract astrocytoma 11.7
29 mixed astrocytoma-ependymoma-oligodendroglioma 11.7
30 childhood brainstem astrocytoma 11.7
31 adult brainstem astrocytoma 11.7
32 cauda equina intradural extramedullary astrocytoma 11.6
33 cerebellar astrocytoma, childhood 11.6
34 oligoastrocytoma 11.6
35 melanoma and neural system tumor syndrome 11.6
36 glioma susceptibility 1 11.5
37 li-fraumeni syndrome 11.2
38 tuberous sclerosis 11.2
39 glioblastoma multiforme 11.2
40 diencephalic syndrome 11.1
41 pleomorphic xanthoastrocytoma 11.0
42 adult infiltrating astrocytic neoplasm 10.8
43 subependymal glioma 10.8
44 glioma susceptibility 9 10.7
45 glioma susceptibility 2 10.7
46 glioblastoma 3 10.7
47 childhood cerebellar astrocytic neoplasm 10.6
48 liver fibrosarcoma 10.4 GFAP TP53
49 cervical adenoid cystic carcinoma 10.4 GFAP NF1 TP53
50 glioblastoma 10.4

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

GenomeRNAi Phenotypes related to Astrocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Astrocytoma:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 CDKN2A GFAP MDM2 NF1 NRN1 OLIG2
2 homeostasis/metabolism MP:0005376 10.42 GFAP IDH1 IL1B MDM2 MGMT NF1
3 cellular MP:0005384 10.41 EGFR GFAP MDM2 NF1 NRN1 OLIG2
4 growth/size/body region MP:0005378 10.38 CCND1 CDK4 CDKN2A EGFR GFAP IDH1
5 mortality/aging MP:0010768 10.37 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
6 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A EGFR GFAP IL1B MDM2
7 immune system MP:0005387 10.35 MDM2 NF1 CCND1 CDK4 CDKN2A DMBT1
8 digestive/alimentary MP:0005381 10.33 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
9 hematopoietic system MP:0005397 10.3 CCND1 CDK4 CDKN2A EGFR IDH1 IL1B
10 nervous system MP:0003631 10.28 CDK4 CDKN2A EGFR GFAP IL1B MDM2
11 endocrine/exocrine gland MP:0005379 10.27 NF1 PTEN TP53 VEGFA CCND1 CDK4
12 neoplasm MP:0002006 10.27 CCND1 CDK4 CDKN2A DMBT1 EGFR IL1B
13 integument MP:0010771 10.26 MDM2 NF1 PTEN CCND1 CDK4 CDKN2A
14 embryo MP:0005380 10.24 VEGFA CDK4 CDKN2A DMBT1 EGFR MDM2
15 muscle MP:0005369 10.18 CDK4 CDKN2A EGFR GFAP MDM2 NF1
16 liver/biliary system MP:0005370 10.11 CDK4 CDKN2A EGFR MDM2 NF1 PTEN
17 normal MP:0002873 10.11 CCND1 CDK4 EGFR GFAP MDM2 NF1
18 no phenotypic analysis MP:0003012 10.01 CDKN2A EGFR MDM2 MGMT NRN1 OLIG2
19 pigmentation MP:0001186 9.87 CDK4 CDKN2A EGFR MDM2 NF1 PTEN
20 renal/urinary system MP:0005367 9.86 CDK4 DMBT1 EGFR MDM2 NF1 PTEN
21 respiratory system MP:0005388 9.85 CCND1 CDKN2A EGFR IDH1 MGMT NF1
22 skeleton MP:0005390 9.7 CCND1 CDKN2A EGFR IDH1 IL1B MDM2
23 vision/eye MP:0005391 9.32 CCND1 CDK4 CDKN2A EGFR GFAP NF1

Drugs & Therapeutics for Astrocytoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Temodar 17 46 TEMOZOLOMIDE Schering-Plough Approved August 1999

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
4
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
6
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
11 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
14 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
16
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
17
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
18
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
19
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
20
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
21
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
22
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
23
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
24
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
25
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
26
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
27
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
28
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
29
Tranexamic Acid Approved Phase 3 1197-18-8 5526
30
Thiotepa Approved Phase 2, Phase 3, Phase 1 52-24-4 5453
31
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
32
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
33
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
34
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
35
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
36
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
37
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
38
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
40
chloroquine Approved, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
41
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
42
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
43
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
44
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 15158-11-9, 7440-50-8 27099
45
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
46
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
47
Leflunomide Approved, Investigational Phase 3,Phase 2 75706-12-6 3899
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
50
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311

Interventional clinical trials:

(show top 50) (show all 1308)
id Name Status NCT ID Phase
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
3 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
6 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
7 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3
8 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3
9 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
10 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
11 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
12 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
13 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
14 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
15 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3
16 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
17 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
18 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
19 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3
20 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3
21 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
22 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
23 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
24 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
25 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3
26 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
27 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
29 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
30 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3
31 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3
32 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3
33 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
34 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
35 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3
36 A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3
37 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
38 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
39 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3
40 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3
41 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3
42 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
43 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
44 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
45 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
46 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3
47 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
48 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3
49 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
50 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

id Genetic test Affiliating Genes
1 Astrocytoma 29

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

39
Brain, Spinal Cord, Endothelial, Breast, Cerebellum, Pineal, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Astrocytoma:

18
The Cerebrum

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 2190)
id Title Authors Year
1
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
2
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
3
Desmoplastic infantile astrocytoma and ganglioglioma: case report and review of the literature. ( 27668845 )
2017
4
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
5
Testin (TES) as a candidate tumour suppressor and prognostic marker in human astrocytoma. ( 27899997 )
2016
6
Is Upregulation of Aquaporin 4-M1 Isoform Responsible for the Loss of Typical Orthogonal Arrays of Particles in Astrocytomas? ( 27483250 )
2016
7
Spontaneous aneurysmal subarachnoid haemorrhage in a child with multiply recurrent posterior fossa juvenile pilocytic astrocytoma. ( 27927709 )
2016
8
miRNA-429 Inhibits Astrocytoma Proliferation and Invasion by Targeting BMI1. ( 27663885 )
2016
9
Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). ( 27860334 )
2016
10
miR-101 reverses hypomethylation of the PRDM16 promoter to disrupt mitochondrial function in astrocytoma cells. ( 26701852 )
2016
11
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma. ( 27082208 )
2016
12
Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. ( 26188054 )
2016
13
Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells. ( 27130674 )
2016
14
Spontaneous complete regression of hypothalamic pilocytic astrocytoma after partial resection in a child, complicated with Stevens-Johnson syndrome: a case report and literature review. ( 26662551 )
2016
15
Hypothalamic-Optochiasmatic Pilocytic Astrocytoma Associated with Occipital and Sacral Spinal Cavernomas: A Mere Coincidence or a True Association? ( 27004758 )
2016
16
Infratentorial ganglioglioma mimicking pilocytic astrocytoma. ( 27936528 )
2016
17
Expression patterns of Wnt signaling component, secreted frizzleda89related protein 3 in astrocytoma and glioblastoma. ( 27035837 )
2016
18
Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation. ( 27860162 )
2016
19
Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. ( 28009226 )
2016
20
Cranial pilocytic astrocytoma with spinal drop metastasis in an adult: case report and literature review. ( 27535634 )
2016
21
Retraction: Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis. ( 26685762 )
2016
22
Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. ( 27864706 )
2016
23
Clinical Factors for Prognosis and Treatment Guidance of Spinal Cord Astrocytoma. ( 27559457 )
2016
24
Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. ( 26722760 )
2016
25
MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma. ( 27757570 )
2016
26
Coexistent dysembryoplastic neuroepithelial tumour and pilocytic astrocytoma. ( 27695565 )
2016
27
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
28
Massive Calcified Cerebellar Pilocytic Astrocytoma with Rapid Recurrence : A Rare Case. ( 27651876 )
2016
29
Pendular Nystagmus Associated With Cerebral Pylomixoid Astrocytoma. ( 27184692 )
2016
30
Progesterone promotes cell migration, invasion and cofilin activation in human astrocytoma cells. ( 26639431 )
2016
31
Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report. ( 27690251 )
2016
32
Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex. ( 26929034 )
2016
33
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ( 27013816 )
2016
34
A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation. ( 26984877 )
2016
35
Optic nerve astrocytoma in a dog. ( 27648262 )
2016
36
A novel mutation in NF1 is associated with diverse intra-familial phenotypic variation and astrocytoma in a Chinese family. ( 27234610 )
2016
37
Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1. ( 26897750 )
2016
38
Parietal pilomyxoid astrocytoma with recurrence in 10 months: A case report and review of literature. ( 27366287 )
2016
39
Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma. ( 27502785 )
2016
40
Suprasellar pilocytic astrocytoma in an adult with hemorrhage and leptomeningeal dissemination: case report and review of literature. ( 27920871 )
2016
41
Granular cell astrocytoma: report of a case and review of the literature. ( 27125869 )
2016
42
Region-Specific Dok2 Overexpression Associates with Poor Prognosis in Human Astrocytoma. ( 27975172 )
2016
43
Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. ( 27656320 )
2016
44
Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma. ( 26185030 )
2016
45
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. ( 28002790 )
2016
46
Caveolin-1 Regulates the P2Y2 Receptor Signaling in Human 1321N1 Astrocytoma Cells. ( 27129210 )
2016
47
Diffuse astrocytoma arising within a demyelinating plaque. ( 27033061 )
2016
48
Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. ( 27608415 )
2016
49
Cervical spinal pilocytic astrocytoma. ( 26916806 )
2016
50
Post-operative accidental diagnosis of intra-cerebellar astrocytoma in an emergency appendicectomy case. ( 26962259 )
2016

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
3 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
5 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
6 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
7 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
8 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Astrocytoma:

9 (show top 50) (show all 1664)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10672 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade I c.577C>T p.H193Y 5
2 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma Grade IV c.2140C>T p.P714S 4
3 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade IV c.266C>T p.P89L 4
4 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2044T>A p.C682S 4
5 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2043G>C p.Q681H 4
6 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma Grade IV c.1517G>C p.R506T 4
7 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14D 4
8 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2162T>G p.V721G 4
9 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2176G>A p.D726N 4
10 COSM40870 ZFC3H1 central nervous system,brain,glioma,astrocytoma Grade IV c.1055G>A p.S352N 4
11 COSM40793 ZFAT central nervous system,brain,glioma,astrocytoma Grade IV c.1006G>A p.V336M 4
12 COSM40680 ZEB1 central nervous system,brain,glioma,astrocytoma Grade IV c.1913C>T p.S638L 4
13 COSM41152 ZC3H6 central nervous system,brain,glioma,astrocytoma Grade IV c.2254G>T p.G752* 4
14 COSM40778 ZBTB4 central nervous system,brain,glioma,astrocytoma Grade IV c.2842C>T p.L948F 4
15 COSM40777 ZBTB24 central nervous system,brain,glioma,astrocytoma Grade IV c.1886C>T p.P629L 4
16 COSM39508 ZBTB21 central nervous system,brain,glioma,astrocytoma Grade IV c.997G>A p.G333S 4
17 COSM40776 ZBTB16 central nervous system,brain,glioma,astrocytoma Grade IV c.413C>T p.A138V 4
18 COSM41039 YWHAH central nervous system,brain,glioma,astrocytoma Grade IV c.169C>T p.R57* 4
19 COSM40774 YTHDC2 central nervous system,brain,glioma,astrocytoma Grade IV c.782C>T p.A261V 4
20 COSM39272 XPO7 central nervous system,brain,glioma,astrocytoma Grade IV c.1157G>A p.R386Q 4
21 COSM21780 XAB2 central nervous system,brain,glioma,astrocytoma Grade IV c.849C>A p.I283I 4
22 COSM39469 WNK2 central nervous system,brain,glioma,astrocytoma Grade IV c.3757G>A p.A1253T 4
23 COSM40770 WNK1 central nervous system,brain,glioma,astrocytoma Grade IV c.5293G>A p.G1765S 4
24 COSM40769 WFS1 central nervous system,brain,glioma,astrocytoma Grade IV c.573G>A p.K191K 4
25 COSM40767 WEE1 central nervous system,brain,glioma,astrocytoma Grade IV c.765G>A p.K255K 4
26 COSM40766 WDTC1 central nervous system,brain,glioma,astrocytoma Grade IV c.1118C>T p.A373V 4
27 COSM40764 WDR6 central nervous system,brain,glioma,astrocytoma Grade IV c.1170C>T p.F390F 4
28 COSM40762 WDR34 central nervous system,brain,glioma,astrocytoma Grade IV c.475G>A p.A159T 4
29 COSM40761 WDR34 central nervous system,brain,glioma,astrocytoma Grade IV c.1484C>T p.T495I 4
30 COSM39468 WDR24 central nervous system,brain,glioma,astrocytoma Grade IV c.790C>T p.R264C 4
31 COSM40758 WDFY3 central nervous system,brain,glioma,astrocytoma Grade IV c.1126C>T p.H376Y 4
32 COSM40234 WASHC4 central nervous system,brain,glioma,astrocytoma Grade IV c.367+1G>A p.? 4
33 COSM40754 VPS45 central nervous system,brain,glioma,astrocytoma Grade IV c.370G>A p.E124K 4
34 COSM40753 VPS41 central nervous system,brain,glioma,astrocytoma Grade IV c.1830G>A p.Q610Q 4
35 COSM39977 VPS13B central nervous system,brain,glioma,astrocytoma Grade IV c.1913C>T p.T638I 4
36 COSM41129 VPS13B central nervous system,brain,glioma,astrocytoma Grade IV c.9845A>C p.K3282T 4
37 COSM40751 VPS13A central nervous system,brain,glioma,astrocytoma Grade IV c.7400G>A p.G2467D 4
38 COSM40750 VN2R1P central nervous system,brain,glioma,astrocytoma Grade IV c.1753C>T p.P585S 4
39 COSM40748 VIPR2 central nervous system,brain,glioma,astrocytoma Grade IV c.598G>A p.V200M 4
40 COSM39478 VIPAS39 central nervous system,brain,glioma,astrocytoma Grade IV c.1200G>C p.K400N 4
41 COSM39246 VEGFD central nervous system,brain,glioma,astrocytoma Grade IV c.694A>G p.K232E 4
42 COSM40746 VDR central nervous system,brain,glioma,astrocytoma Grade IV c.1135C>T p.L379F 4
43 COSM40745 VCL central nervous system,brain,glioma,astrocytoma Grade IV c.1369C>T p.P457S 4
44 COSM40239 VAT1L central nervous system,brain,glioma,astrocytoma Grade IV c.415G>A p.V139I 4
45 COSM40742 VANGL1 central nervous system,brain,glioma,astrocytoma Grade IV c.634C>T p.R212W 4
46 COSM40741 USP8 central nervous system,brain,glioma,astrocytoma Grade IV c.237C>T p.F79F 4
47 COSM40740 USP11 central nervous system,brain,glioma,astrocytoma Grade IV c.2164G>A p.V722M 4
48 COSM54498 USO1 central nervous system,brain,glioma,astrocytoma Grade IV c.749C>T p.A250V 4
49 COSM1626815 USH2A central nervous system,brain,glioma,astrocytoma Grade IV c.3665C>T p.A1222V 4
50 COSM2157525 USH2A central nervous system,brain,glioma,astrocytoma Grade IV c.14080T>A p.S4694T 4

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

Pathways related to Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCND1 CDK4 CDKN2A EGFR GFAP IL1B
2
Show member pathways
12.97 CCND1 CDK4 CDKN2A EGFR MDM2 NF1
3
Show member pathways
12.7 CCND1 CDK4 MDM2 MGMT TP53
4 12.63 CCND1 CDK4 CDKN2A EGFR MDM2 PTEN
5
Show member pathways
12.61 CCND1 CDK4 CDKN2A MDM2 TP53
6 12.59 CCND1 CDK4 EGFR MDM2 PTEN TP53
7 12.53 CCND1 CDK4 CDKN2A MDM2 MGMT TP53
8 12.5 CCND1 CDKN2A EGFR MDM2 PTEN TP53
9 12.42 CCND1 CDK4 CDKN2A MDM2 TP53
10
Show member pathways
12.41 CCND1 MDM2 PTEN TP53
11
Show member pathways
12.41 CCND1 EGFR MDM2 PTEN TP53
12
Show member pathways
12.39 CCND1 CDK4 CDKN2A MDM2 PTEN TP53
13
Show member pathways
12.37 CCND1 CDK4 CDKN2A TP53
14
Show member pathways
12.33 CCND1 EGFR MDM2 TP53
15 12.33 CCND1 EGFR MDM2 TP53 VEGFA
16 12.32 CCND1 CDK4 CDKN2A MDM2 TP53
17
Show member pathways
12.29 CCND1 CDK4 MDM2 PTEN TP53
18 12.22 CCND1 EGFR TP53 VEGFA
19
Show member pathways
12.19 CCND1 CDK4 EGFR MDM2 PTEN TP53
20
Show member pathways
12.15 CCND1 EGFR MDM2 PTEN
21 12.14 CCND1 MDM2 PTEN TP53
22
Show member pathways
12.12 CCND1 EGFR MDM2 PTEN
23 12.1 EGFR MDM2 PTEN TP53
24
Show member pathways
12.1 CCND1 CDK4 EGFR NF1
25 12.03 CCND1 IL1B TP53 VEGFA
26 12.02 CCND1 CDKN2A MDM2 PTEN TP53
27
Show member pathways
12.01 CCND1 CDK4 CDKN2A EGFR MDM2 TP53
28
Show member pathways
12 EGFR GFAP MDM2 S100B
29 11.96 CCND1 CDK4 IL1B VEGFA
30 11.96 CDKN2A IL1B MDM2 PTEN TP53
31 11.96 CCND1 CDK4 EGFR GFAP IL1B TP53
32 11.95 CCND1 CDK4 EGFR MDM2 NF1 PTEN
33 11.93 CCND1 CDK4 CDKN2A MDM2 MGMT PTEN
34 11.91 CCND1 EGFR MDM2 PTEN
35 11.88 CCND1 CDK4 MDM2 TP53
36 11.86 CCND1 CDK4 PTEN TP53
37 11.76 CDKN2A MDM2 TP53
38
Show member pathways
11.76 CDKN2A MDM2 TP53
39 11.75 GFAP NES OLIG2 S100B SYP VEGFA
40 11.74 CDKN2A MDM2 TP53 VEGFA
41
Show member pathways
11.73 CCND1 EGFR VEGFA
42 11.73 EGFR IDH1 PTEN TP53
43
Show member pathways